OBJECTIVE: Our goal was to assess the efficacy and safety of intravenous (IV) secukinumab for the treatment of adults with active axial spondyloarthritis (axSpA) in INVIGORATE-1. METHODS: INVIGORATE-1 (NCT04156620) was a randomized, double-blind, parallel-group, phase 3 trial in patients with active axSpA (either radiographic or nonradiographic). Patients were randomized one to one to receive IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every four weeks) or IV placebo for 16 weeks. After week 16, patients randomized to placebo were switched to IV secukinumab (3 mg/kg every four weeks), and patients randomized to secukinumab continued treatment through week 52. The primary endpoint was the Assessment of SpondyloArthritis International Society (ASAS40) response at week 16. Safety was evaluated through week 60. RESULTS: Among patients initially randomized to IV secukinumab (n = 264) or placebo (n = 262), 86.0% and 88.9% completed the entire 60-week study period, respectively. A higher proportion of patients receiving secukinumab versus placebo met the primary endpoint (ASAS40 response) at week 16 (40.9% vs 22.9%; P < 0.0001). By week 24, patients who switched from placebo to secukinumab at week 16 achieved ASAS40 response rates comparable to those in patients originally randomized to secukinumab. All secondary efficacy endpoints were met at week 16, and responses were sustained through week 52. No new or unexpected safety signals were observed with IV secukinumab. CONCLUSION: IV secukinumab was effective for the treatment of adults with active axSpA over 52 weeks. The safety profile was consistent with that in previous reports on subcutaneous secukinumab.

Altoona Center for Clinical Research Duncansville Pennsylvania

Charles University Prague Czech Republic

Integral Rheumatology and Immunology Specialists Plantation Florida

Medical Plus s r o Uherske Hradiste Czech Republic and Masaryk University Brno Czech Republic

Novartis Pharma AG Basel Switzerland

NZOZ Centrum Medyczne Artur Racewicz Bialystok Poland

Oregon Health and Science University Portland Oregon

Zobrazit více v PubMed

Navarro‐Compán V, Sepriano A, El‐Zorkany B, et al. Axial spondyloarthritis. Ann Rheum Dis 2021;80(12):1511–1521. PubMed

Michelena X, López‐Medina C, Marzo‐Ortega H. Non‐radiographic versus radiographic axSpA: what's in a name? Rheumatology (Oxford) 2020;59(suppl 4):iv18–iv24. PubMed PMC

Robinson PC, van der Linden S, Khan MA, et al. Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nat Rev Rheumatol 2021;17(2):109–118. PubMed

Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68(6):777–783. PubMed

Schwartzman S, Ruderman EM. A road map of the axial spondyloarthritis continuum. Mayo Clin Proc 2022;97(1):134–145. PubMed

Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS‐EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 2023;82(1):19–34. PubMed

Braun J, Kiltz U, Buhring B, et al. Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence. Ther Adv Musculoskelet Dis 2021;13:1759720X211041854. PubMed PMC

Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double‐blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021;80(5):582–590. PubMed PMC

Baeten D, Sieper J, Braun J, et al; MEASURE 1 Study Group; MEASURE 2 Study Group. Secukinumab, an interleukin‐17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015;373(26):2534–2548. PubMed

Marzo‐Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3‐year results from the phase III trial, MEASURE 2. RMD Open 2017;3(2):e000592. PubMed PMC

Pavelka K, Kivitz AJ, Dokoupilova E, et al; MEASURE 3 study group . Secukinumab 150/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3‐year results from the phase 3 MEASURE 3 study. ACR Open Rheumatol 2020;2(2):119–127. PubMed PMC

Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo‐controlled phase III study. Arthritis Rheumatol 2021;73(1):110–120. PubMed PMC

Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double‐blind phase 3 study, MEASURE 3. Arthritis Res Ther 2017;19(1):285. PubMed PMC

Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(suppl 2):ii1–ii44. PubMed

Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21(12):2286–2291. PubMed

van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteri. Arthritis Rheum 1984;27(4):361–368. PubMed

Wallman JK, Kapetanovic MC, Petersson IF, et al. Comparison of non‐radiographic axial spondyloarthritis and ankylosing spondylitis patients–baseline characteristics, treatment adherence, and development of clinical variables during three years of anti‐TNF therapy in clinical practice. Arthritis Res Ther 2015;17:378. PubMed PMC

Poddubnyy D, Haibel H, Braun J, et al. Brief report: clinical course over two years in patients with early nonradiographic axial spondyloarthritis and patients with ankylosing spondylitis not treated with tumor necrosis factor blockers: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheumatol 2015;67(9):2369–2375. PubMed

Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21(12):2281–2285. PubMed

Ware JE Jr, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Med Care 1992;30(6):473–483. PubMed

Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62(1):20–26. PubMed PMC

Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28(2):193–213. PubMed

Jones SD, Porter J, Garrett SL, et al. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 1995;22(8):1609. PubMed

Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009;68(6):948–953. PubMed

Heuft‐Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62(2):127–132. PubMed PMC

Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104‐week results from MEASURE 4 study. Rheumatol Ther 2018;5(2):447–462. PubMed PMC

Huang F, Sun F, Wan WG, et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52‐week, phase III China‐centric study, MEASURE 5. Chin Med J (Engl) 2020;133(21):2521–2531. PubMed PMC

Deodhar AA, Shiff NJ, Gong C, et al. Efficacy and safety of intravenous golimumab in ankylosing spondylitis patients with early and late disease through one year of the GO‐ALIVE study. J Clin Rheumatol 2022;28(5):270–277. PubMed PMC

Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104‐week results of the GO‐RAISE study. Ann Rheum Dis 2012;71(5):661–667. PubMed PMC

Cosentyx® (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, October 2023.

van der Heijde D, Dijkmans B, Geusens P, et al; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group . Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo‐controlled trial (ASSERT). Arthritis Rheum 2005;52(2):582–591. PubMed

Overton PM, Shalet N, Somers F, et al. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence 2021;15:811–834. PubMed PMC

Bolge SC, Eldridge HM, Lofland JH, et al. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Prefer Adherence 2017;11:661–669. PubMed PMC